Gynecologic Cancers

9 protocols meet the specified criteria.

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • EAY191-A3

    A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancer

  • EAY191-N4

    A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

  • EAY191-N5

    A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

  • GOG-3043

    A Randomized Controlled Trial of Robotic versus Open Surgery for Cervical Cancer (ROCC trial)

  • NRG-CC008

    A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCk)

  • NRG-GY019

    A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

  • NRG-GY026

    A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) in HER2 Positive, Stage I-IV Endometrial Cancer